Study NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma
Soft tissue sarcoma (STS) is a kind of solid tumor with high heterogeneity. There is no standard second-line treatment plan for patients who have failed first-line treatment. NY-ESO-1, a cancer testis antigen, is highly expressed in soft tissue tumors and is an ideal therapeutic target. Investigators aim to testify the safety and efficacy of NY-ESO-1 TCR-T cell in advanced soft tissue sarcoma.
• Aged 18-70 (≥ 18, ≤ 70), regardless of gender;
• Subjects voluntarily participate in the study, and they or their legal guardians sign the Informed Consent Form;
• Late recurrent or metastatic soft tissue sarcoma confirmed by histopathology; Progress after receiving first-line treatment;
• According to RECIST 1.1 standard, there are clear assessable lesions;
• The expression of NY-ESO-1 in tumor tissue was confirmed by immunohistochemical staining; HLA-A configuration is 02/01;
• Within 2 weeks before cell therapy, no antibody drugs were used;
• ECOG score is 0-2;
• The subject has no contraindication for peripheral blood collection;
• The expected survival period is more than 3 months.